Flavonoid-rich extract of Chromolaena odorata modulate circulating GLP-1 in Wistar rats: computational evaluation of TGR5 involvement
Abstract Chromolaena odorata is a major bio-resource in folkloric treatment of diabetes. In the present study, its anti-diabetic component and underlying mechanism were investigated. A library containing 140 phytocompounds previously characterized from C. odorata was generated and docked (Autodock Vina) into homology models of dipeptidyl peptidase (DPP)-4, Takeda-G-protein-receptor-5 (TGR5), glucagon-like peptide 1 (GLP1) receptor, renal sodium dependent glucose transporter (SGLUT)-1/2 and nucleotide-binding oligomerization domain (NOD) proteins 1&2. GLP-1 gene (RT-PCR) modulation and its release (EIA) by C. odorata were confirmed in vivo. From the docking result above, TGR5 was identified as a major target for two key C. odorata flavonoids (5,7-dihydroxy-6-4-dimethoxyflavanone and homoesperetin-7-rutinoside); sodium taurocholate and C. odorata powder included into the diet of the animals both raised the intestinal GLP-1 expression versus control (p < 0.05); When treated with flavonoid-rich extract of C. odorata (CoF) or malvidin, circulating GLP-1 increased by 130.7% in malvidin-treated subjects (0 vs. 45 min). CoF treatment also resulted in 128.5 and 275% increase for 10 and 30 mg/kg b.w., respectively. Conclusions: The results of this study support that C. odorata flavonoids may modulate the expression of GLP-1 and its release via TGR5. This finding may underscore its anti-diabetic potency..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
3 Biotech - 8(2018), 2 vom: 13. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Omotuyi, Olaposi Idowu [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Springer-Verlag GmbH Germany, part of Springer Nature 2018 |
|---|
| doi: |
10.1007/s13205-018-1138-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR030856892 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR030856892 | ||
| 003 | DE-627 | ||
| 005 | 20230519133339.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13205-018-1138-x |2 doi | |
| 035 | |a (DE-627)SPR030856892 | ||
| 035 | |a (SPR)s13205-018-1138-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Omotuyi, Olaposi Idowu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Flavonoid-rich extract of Chromolaena odorata modulate circulating GLP-1 in Wistar rats: computational evaluation of TGR5 involvement |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer-Verlag GmbH Germany, part of Springer Nature 2018 | ||
| 520 | |a Abstract Chromolaena odorata is a major bio-resource in folkloric treatment of diabetes. In the present study, its anti-diabetic component and underlying mechanism were investigated. A library containing 140 phytocompounds previously characterized from C. odorata was generated and docked (Autodock Vina) into homology models of dipeptidyl peptidase (DPP)-4, Takeda-G-protein-receptor-5 (TGR5), glucagon-like peptide 1 (GLP1) receptor, renal sodium dependent glucose transporter (SGLUT)-1/2 and nucleotide-binding oligomerization domain (NOD) proteins 1&2. GLP-1 gene (RT-PCR) modulation and its release (EIA) by C. odorata were confirmed in vivo. From the docking result above, TGR5 was identified as a major target for two key C. odorata flavonoids (5,7-dihydroxy-6-4-dimethoxyflavanone and homoesperetin-7-rutinoside); sodium taurocholate and C. odorata powder included into the diet of the animals both raised the intestinal GLP-1 expression versus control (p < 0.05); When treated with flavonoid-rich extract of C. odorata (CoF) or malvidin, circulating GLP-1 increased by 130.7% in malvidin-treated subjects (0 vs. 45 min). CoF treatment also resulted in 128.5 and 275% increase for 10 and 30 mg/kg b.w., respectively. Conclusions: The results of this study support that C. odorata flavonoids may modulate the expression of GLP-1 and its release via TGR5. This finding may underscore its anti-diabetic potency. | ||
| 650 | 4 | |a Flavonoids |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a TGR5 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a GLP-1 |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Nash, Oyekanmi |4 aut | |
| 700 | 1 | |a Inyang, Olumide Kayode |4 aut | |
| 700 | 1 | |a Ogidigo, Joyce |4 aut | |
| 700 | 1 | |a Enejoh, Ojochenemi |4 aut | |
| 700 | 1 | |a Okpalefe, Okiemute |4 aut | |
| 700 | 1 | |a Hamada, Tsuyoshi |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t 3 Biotech |d Berlin : Springer, 2011 |g 8(2018), 2 vom: 13. Feb. |w (DE-627)SPR030851394 |w (DE-600)2600522-0 |x 2190-5738 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2018 |g number:2 |g day:13 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13205-018-1138-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2018 |e 2 |b 13 |c 02 | ||